NIS to examine the effectiveness and safety of durvalumab and olaparib in patients with endometrial cancer (DUOLife)

Trial Identifier: D9311R00001
Sponsor: AstraZeneca
Collaborator:
North-Eastern German Society of Gynecological Oncology (NOGGO e.V.)
Start Date: May 2025
Primary Completion Date: September 2028
Study Completion Date: September 2028
Condition: Endometrial Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Germany Amberg, Germany
Germany Bad Nauheim, Germany
Germany Bautzen, Germany
Germany Berlin, Germany
Germany Bielefeld, Germany
Germany Borna, Germany
Germany Bottrop, Germany
Germany Brandenburg an der Havel, Germany
Germany Braunschweig, Germany
Germany Dessau, Germany
Germany Dresden, Germany
Germany Ebersberg, Germany
Germany Essen, Germany
Germany Goslar, Germany
Germany Guetersloh, Germany
Germany Heilbronn, Germany
Germany Krefeld, Germany
Germany Landshut, Germany
Germany Leipzig, Germany
Germany Limburg, Germany
Germany Lueneburg, Germany
Germany Mainz, Germany
Germany Muenchen, Germany
Germany Nuernberg, Germany
Germany Plauen, Germany
Germany Rotenburg (Wuemme), Germany
Germany Siegen, Germany
Germany Solingen, Germany
Germany Torgau, Germany
Germany Unna, Germany
Germany Weningerode, Germany
Germany Winnenden, Germany
Germany Worms, Germany